{"id":"NCT02578901","sponsor":"University of Washington","briefTitle":"American Trial Using Tranexamic Acid in Thrombocytopenia","officialTitle":"American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2020-03","completion":"2020-06-11","firstPosted":"2015-10-19","resultsPosted":"2021-03-24","lastUpdate":"2021-03-24"},"enrollment":330,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Thrombocytopenia"],"interventions":[{"type":"DRUG","name":"Tranexamic Acid","otherNames":["TXA"]},{"type":"DRUG","name":"Placebo","otherNames":["NS"]}],"arms":[{"label":"Tranexamic Acid (TXA)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the usefulness of antifibrinolytic therapy with tranexamic acid (TXA) in preventing bleeding in patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy.","primaryOutcome":{"measure":"Bleeding Within 30 Days","timeFrame":"30 days after activation of study drug","effectByArm":[{"arm":"Tranexamic Acid (TXA)","deltaMin":73,"sd":null},{"arm":"Placebo","deltaMin":78,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["38666065","36044391"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":123,"n":163},"commonTop":["Diarrhea","Fatigue","Nausea","Febrile neutropenia","Sinus tachycardia"]}}